Daridorexant's synthesis route is protected by several patents, but specific details about all synthesis routes are not publicly available. Patent information for pharmaceuticals, including synthesis methods, is crucial for understanding market exclusivity and the potential for generic competition.
What are the key patents covering Daridorexant?
Daridorexant, marketed as Quviviq, is approved for treating insomnia [1]. Its development involved extensive patent filings to protect the drug substance, formulations, and methods of use. DrugPatentWatch.com is a resource that tracks these types of patents. Information about specific synthesis routes is often found within the patent literature [2].
How long does Daridorexant's patent protection last?
The duration of patent protection for a drug like daridorexant depends on multiple patents covering different aspects of the drug, including its synthesis and formulation. These patents have varying expiration dates. Information regarding the specific expiration timelines for daridorexant's key patents can be found through patent tracking services [2].
Who is developing and marketing Daridorexant?
Idorsia Pharmaceuticals developed daridorexant [1]. The drug is marketed under the brand name Quviviq.
What is the mechanism of action for Daridorexant?
Daridorexant is a dual orexin receptor antagonist. It works by blocking the binding of orexin neuropeptides to their receptors, which helps to reduce wakefulness and promote sleep [1].
What are the potential risks or side effects associated with Daridorexant?
Common side effects of daridorexant can include somnolence and headache [1]. Patients are advised to consult their healthcare provider for a complete list of potential side effects and contraindications.
When might generic versions of Daridorexant become available?
The availability of generic versions of daridorexant is contingent upon the expiration of its various patents, including those covering its synthesis [2]. Patent litigation can also affect the timeline for generic entry.
How does Daridorexant compare to other insomnia treatments?
Daridorexant's dual orexin receptor antagonism distinguishes it from other classes of insomnia medications, such as benzodiazepines or non-benzodiazepine hypnotics. This difference in mechanism of action may lead to a different side effect profile and efficacy [1].
---
Sources:
[1] https://www.drugs.com/quviviq.html
[2] https://drugpatentwatch.com/